Reports suggest that the UK government has agreed to pay higher prices for prescription medicines, with the suggestion that this is a response to a demand from the US Trump administration. Meanwhile, some companies in Australia have paused the progression of PBS listings in response to MFN uncertainty.
UK moves to pricing changes as Australian-based companies baulk at listings
June 5, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Hospital pharmacists use Rare Cancers Awareness Day to call for reform
June 27, 2025 - - Latest News -
MedAdvisor progressing review, including the potential sale of ANZ business
June 27, 2025 - - Latest News -
Mark Butler retains position on critical Cabinet committee
June 26, 2025 - - Latest News -
New Zealand to streamline access to ADHD treatments
June 26, 2025 - - Latest News -
CLEO strengthens FDA submission following Access to globally recognised Biobank
June 25, 2025 - - Australian Biotech -
Leukaemia Foundation calls for urgent action to address diagnosis and treatment gaps
June 25, 2025 - - Latest News -
QBiotics' candidate produces strong efficacy result in soft tissue sarcoma trial
June 25, 2025 - - Latest News